Seizures and the natural history of world health organization grade II gliomas: A review

Neurosurgery

Volumn 68, Issue 5, 2011, Pages 1326-1333

  Smits, Anja ^a   Duffau, Hugues ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

Epilepsy; Low grade glioma; Survival; Tumor progression

Indexed keywords

FOTEMUSTINE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; GLIOMA; HUMAN; INTRACTABLE EPILEPSY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; REOPERATION; REVIEW; SEIZURE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

BRAIN NEOPLASMS; GLIOMA; HUMANS; POSTOPERATIVE CARE; SEIZURES; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 79954996186     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e31820c3419     Document Type: Review

References (60)

1. Davies FG, Preston-Martin S. Russell & Rubenstein's Pathology ofTumors in the Nervous System. In: Bigner DD, McLendon RE, Bruner JM, eds. Arnold. London: 1998.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumors ofthe central nervous system. Acta Neuropathol. 2007;114(2):97-109. (Pubitemid 47103521)
3. Ohgaki H, Kleihues P. Epidemiology and etiology ofgliomas. Acta Neuropathol. 2005;109(1):93-108.
4. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade gliomas in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997;15(4):1294-1301. (Pubitemid 27167360)
5. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421-430. (Pubitemid 46551867)
6. Klein M, Engelberts NH, van der Ploeg HM, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality oflife. Ann Neurol. 2003;54(4): 514-520. (Pubitemid 37176548)
7. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset ofgrade II gliomas. Ann Neurol. 2003;53(4):524-528. (Pubitemid 36373265)
8. Rees J, Watt H, Jäger HR, et al. Volumes and growth rates ofuntreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol. 2009;72(1):54-64.
9. El-Hateer H, Souhami L, Roberge D, et al. Low-grade oligodendroglioma: an indolent but incurable disease? JNeurosurg. 2009;111(2):265-271.
10. Zlatescu MC, TehraniYazdi A, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001;61(18):6713-6715. (Pubitemid 32896492)
11. Chang EF, Potts MB, Keles GE, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008;108(2): 227-235. (Pubitemid 351213284)
12. Brogna C, Gil Robles S, Duffau H. Brain tumors and epilepsy. Expert Rev Neurother. 2008;8(6):941-955. (Pubitemid 351872598)
13. Beaumont A, Whittle IR. The pathogenesis oftumour associated epilepsy. Acta Neurochir (Wien). 2000;142(1):1-15.
14. Schaller B, Ruegg SJ. Brain tumor and seizures: pathophysiology and its im-plications for treatment revisited. Epilepsia. 2003;44(9):1223-1232. (Pubitemid 37100049)
15. Rosati A, Tomassini A, Pollo B, et al. Epilepsy in cerebral glioma: timing of appearance and histological correlations. JNeurooncol. 2009;93(3):395-400.
16. Van den Bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. Crit Rev Oncol Hematol. 2008;66(3):262-272.
17. Duffau H, Capelle L. Preferential brain locations oflow-grade gliomas. Cancer. 2004;100(12):2622-2626.
18. Hwang SL, Lin CL, Lee KS, et al. Factors influencing seizures in adult patients with supratentorial astrocytic tumors. Acta Neurochir (Wien). 2004;146(6): 589-594. (Pubitemid 38788795)
19. Danfors T, Ribom D, Berntsson SG, Smits A. Epileptic seizures and survival during early disease in grade 2 gliomas. Eur J Neurol. 2009;16(7):823-831.
20. Bauman G, Fisher B, Watling C, Cairncross JG, Macdonald D. Adult supra-tentorial low-grade glioma: long-term experience at a single institution. Int J Radiat Oncol Biol Phys. 2009;75(5):1401-1407.
21. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20(8):2076-2084. (Pubitemid 34408798)
22. Duffau H. A personal consecutive series of surgically treated 51 cases of insular WHO Grade II glioma: advances and limitations. J Neurosurg. 2009;110(4): 696-708.
23. van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psych. 1998;64(5):581-587. (Pubitemid 28204142)
24. Lote K, Egeland T, Hager B, et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol. 1997;15(9):3129-3140. (Pubitemid 27377505)
25. Soffietti R, Chiò A, Giordana MT, Vasario E, Schiffer D. Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery. 1989;24(5):686-692. (Pubitemid 19115923)
26. Kreth FW, Faist M, Rossner R, Volk B, Ostertag CB. Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. Cancer. 1997;79(2):370-379. (Pubitemid 27029902)
27. Piepmeier J, Christopher S, Spencer D, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery. 1996;38(5):872-878.
28. Bartolomei JC, Christopher S, Vives K, Spencer DD, Piepmeier JM. Low-grade gliomas ofchronic epilepsy: a distinct clinical and pathological entity. JNeurooncol. 1997;34(1):79-84. (Pubitemid 27270253)
29. Plate KH, Wieser H-G, Yasargil MG, Wiestler OD. Neuropathological findings in 224 patients with temporal lobe epilepsy. Acta Neuropathol. 1994;86(5):433-438.
30. Afra D, Osztie E, Sipos L, Vitanovics D. Preoperative history and postoperative survival ofsupratentorial low-grade astrocytomas. Br J Neurosurg. 1999;13(3):299-305. (Pubitemid 29304502)
31. Piepmeier JM. Current concepts in the evaluation and management ofWHO grade II gliomas. JNeurooncol. 2009;92(3):253-259.
32. Schramm J, Luyken C, Urbach H, Fimmers R, Blümcke I. Evidence for a clinically distinct new subtype ofgrade II astrocytomas in patients with long-term epilepsy. Neurosurgery. 2004;55(2):340-347. (Pubitemid 39014523)
33. Blumcke I, Luyken C, Urbach H, Schramm J, Wiestler OD. An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis. Acta Neuropathol. 2004;107(5):381-388. (Pubitemid 38559246)
34. Devinsky O. Patients with refractory seizures. N Engl J Med. 1999;340(20): 1565-1570. (Pubitemid 29228187)
35. Bauer R, Dobesberger J, Unterhofer C, et al. Outcome of adult patients with temporal lobe tumors and medically refractory epilepsy. Acta Neurochir (Wien). 2007;149(2):1211-1216. (Pubitemid 350265443)
36. Zaatreh MM, Firlik KS, Spencer DD, et al. Temporal lobe tumoral epilepsy: characteristics andpredictors ofsurgical outcome. Neurology. 2003;61(5):636-641. (Pubitemid 37082600)
37. Peraud A, Meschede M, Eisner W, Ilmberger J, Reulen HJ. Surgical resection of grade II astrocytomas in the superior frontal gyrus. Neurosurgery. 2002;50(5): 966-975.
38. Kim OJ, Yong AJ, Chung YS, et al. Significance ofchronic epilepsy in glial tumors and correlation with surgical strategies. J Clin Neurosci. 2004;11(7):702-705. (Pubitemid 39164981)
39. Lombardi D, Marsh R, de Tribolet N. Low grade glioma in intractable epilepsy: lesionectomy versus epilepsy surgery. Acta Neurochir. 1997;68(suppl):70-74.
40. Duffau H. Surgery of low-grade gliomas: towards a 'functional neurooncology'. Curr Opin Oncol. 2009;21(6):543-549.
41. Duffau H, Capelle L, Lopes M, Bitar A, Sichez JP, van Effenterre R. Medically intractable epilepsy from insular low-grade gliomas: improvement after an ex-tended lesionectomy. Acta Neurochir (Wien). 2002;144(6):563-572.
42. van den Bent MJ, Afra D, de Witte, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985-990. (Pubitemid 41323034)
43. Soffietti R, Borgognone M, Ducati A, et al. Efficacy of radiation therapy on seizures in low-grade astrocytomas. Neuro-Oncol. 2005(suppl):389.
44. Rogers LR, Morris HH, Lupica K. Effect ofcranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology. 1993;43(8):1599-1601. (Pubitemid 23230553)
45. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36(3):549-556. (Pubitemid 26404297)
46. Kiebert GM, Curran D, Aaronson NK, et al. Quality oflife after radiation therapy ofcerebral low-grade gliomas ofthe adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998;34(12):1902-1909. (Pubitemid 28535439)
47. Brada M, Viviers L, Abson C, et al. Phase II study ofprimary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14(12):1715-1721. (Pubitemid 38029041)
48. Pace A, Vidiri A, Galiè E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003; 14(12):1722-1726. (Pubitemid 38029042)
49. Sherman J, Yeoh H, Pouratian N, et al. Impact oftemozolomide chemotherapy on seizure frequency in patients with low-grade glioma. Neuro-Oncol. 2008;832. (abstr)
50. Taillandier L, Duffau H. Epilepsy and insular Grade II gliomas: an in-terdisciplinary point ofview from a retrospective monocentric series of46 cases. Neurosurg Focus. 2009;27(2):E8.
51. Martino J, Taillandier L, Moritz-Gasser S, Gatignol P, Duffau H. Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas. Acta Neurochir (Wien). 2009;151(5):427-436.
52. Wick W, Menn O, Meisner C, et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie. 2005;28(8-9): 391-406.
53. Hildebrand J, Lecaille C, Perennes J, Delattre JY. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology. 2005;65(2):212-215. (Pubitemid 41022363)
54. Pallud J, Mandonnet E, Deroulers C, et al. Pregnancy increases the growth rates of WHO grade II gliomas. Ann Neurol. 2010;67(3):398-404.
55. Ruiz J, Lesser GJ. Low-grade gliomas. Curr Treat Options Oncol. 2009;10 (3-4):231-242.
56. Berntsson SG, Malmer B, Bondy ML, Qu M, Smits A. Tumor-associated epilepsy and glioma: are there common genetic pathways? Acta Oncol. 2009;48(7): 955-963.
57. Wolf HK, Wiestler OD. Surgical pathology ofchronic epileptic seizure disorders. Brain Pathol. 1993;3(4):371-380. (Pubitemid 23349808)
58. Aronica E, Boer K, Becker A, et al. Gene expression profile analysis of epilepsy-associated gangliogliomas. Neuroscience. 2008;151(1):272-292.
59. Gilmore R, Morris H III, Van Ness PC, Gilmore-Pollak W, Estes M. Mirror focus: function of seizure frequency and influence on outcome after surgery. Epilepsia. 1994;35(2):258-263. (Pubitemid 24138807)
60. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3(3):159-168. (Pubitemid 38229950)